Alzheimer's Disease
About Alzheimer's Disease
IXICO has supported important Alzheimer's Disease research since 2007 and continues to assist many pharmaceutical companies in their search for novel therapies. We have provided both MRI and PET imaging biomarkers for over 70 clinical studies in neuroscience, of which, over 30 have been in Alzheimer's disease.
In both EPAD and AMYPAD international consortia projects, IXICO data analysis algorithms have quantitatively analysed brain scans, to maximise the information extracted and increase chances of detecting therapy-induced changes in clinical trials. IXICO's artificial intelligence data analytics will be used to combine imaging with other data captured from patients, to predict the rate of disease progression in individual patients and identify those people who could benefit from enrolment in clinical trials aimed at preventing Alzheimer’s disease.
Experience and capacity
- Experience and capacity to support all phases of AD clinical research from early to late phase studies. Scalable to studies that require the management and analysis of large numbers of data sets.
- Technology-enabled standardisation in imaging and wearables site set-up improves data quality and consistency in global multi-centre trials.
Imaging network
- Network of over 1,500 qualified imaging facilities with established connections to clinical research sites.
- Patient centricity: gaining insights into people living with Alzheimer’s disease coupled with training and technology improves recruitment, retention and support to trial participants.
Expert neuroradiology
- Team of expert Neuro-radiologists performing centralized, real time, standardised safety reads.
- Optimum solutions for delivery of data science including advanced MRI, PET, and wearable technology.
Collaboration
- Collaboration with International Consortia, academic institutions and global networks of Research Sites enables efficient and effective delivery of imaging and other data science.